# Evolent Clinical Guideline 3019 for Rezlidhia™ (olutasidenib)

| Guideline Number: | Applicable Codes | |
|---|---|---|
| Evolent_CG_3019 | | |
| ***"Evolent" refers to Evolent Health LLC and Evolent Specialty Services, Inc.*** | | |
| ***© 2023 - 2026 Evolent. All rights Reserved.*** | | |
| **Original Date:** | **Last Revised Date:** | **Implementation Date:** |
| February 2023 | February 2026 | February 2026 |

# TABLE OF CONTENTS


**STATEMENT** ..... **2**
PURPOSE ..... 2
**INDICATIONS** ..... **2**
ACUTE MYELOID LEUKEMIA (AML) ..... 2
**CONTRAINDICATIONS/WARNINGS** ..... **2**
**EXCLUSION CRITERIA** ..... **2**
**CODING AND STANDARDS** ..... **3**
CODES ..... 3
APPLICABLE LINES OF BUSINESS ..... 4
**POLICY HISTORY** ..... **4**
**LEGAL AND COMPLIANCE** ..... **4**
GUIDELINE APPROVAL ..... 4
*Committee* ..... *4*
DISCLAIMER ..... 4
**REFERENCES** ..... **5**

# STATEMENT

## Purpose

To define and describe the accepted indications for Rezlidhia (olutasidenib) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

Evolent is responsible for processing all medication requests from network ordering providers. Medications not authorized by Evolent may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

# INDICATIONS

**Continuation requests for a not-approvable medication shall be exempt from this Evolent policy provided**

- The member has not experienced disease progression on the requested medication AND
- The requested medication was used within the last year without a lapse of more than 30 days of having an active authorization AND
- Additional medication(s) are not being added to the continuation request.

## Acute Myeloid Leukemia (AML)

- Rezlidhia (olutasidenib) may be used in adult members with relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation as detected by any FDA-approved test.

# CONTRAINDICATIONS/WARNINGS

- US Boxed Warning
  - Differentiation syndrome, which can be fatal, can occur with olutasidenib treatment. Symptoms may include dyspnea, pulmonary infiltrates/pleuropericardial effusion, kidney injury, hypotension, fever, and weight gain. If differentiation syndrome is suspected, withhold olutasidenib and initiate treatment with corticosteroids and hemodynamic monitoring until symptom resolution.

# EXCLUSION CRITERIA

- Disease progression while taking Rezlidhia (olutasidenib) or on any IDH1 inhibitor [e.g., Tibsovo (ivosidenib)].

- Lack of documentation for the detection of IDH1 mutation
- Dosing exceeds single dose limit of Rezlidhia (olutasidenib) 150 mg.
- Treatment with Rezlidhia (olutasidenib) exceeds the maximum limit of 60 (150 mg) capsules/month.
- Investigational use of Rezlidhia (olutasidenib) with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community. Sufficient evidence that is not supported by CMS recognized compendia or acceptable peer reviewed literature is defined as any of the following:
    - Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence.
    - Whether the administered chemotherapy/biologic therapy/immune therapy/targeted therapy/other oncologic therapy regimen is adequately represented in the published evidence.
    - Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. Generally, the definitions of Clinically Meaningful outcomes are those recommended by ASCO, e.g., Hazard Ratio of less than 0.80 and the recommended survival benefit for OS and PFS should be at least 3 months.
    - Whether the experimental design, considering the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover).
    - That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs.
    - That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs.
    - That abstracts (including meeting abstracts) without the full article from the approved peer-reviewed journals lack supporting clinical evidence for determining accepted uses of drugs.

# CODING AND STANDARDS

## Codes

- J8999 - olutasidenib

## Applicable Lines of Business

| | |
|---|---|
| ☐ | CHIP (Children's Health Insurance Program) |
| ☒ | Commercial |
| ☒ | Exchange/Marketplace |
| ☒ | Medicaid |
| ☐ | Medicare Advantage |

# POLICY HISTORY

| Date | Summary |
|---|---|
| February 2026 | • Updated contraindications/warnings section<br>• Updated references |
| February 2025 | • Converted to new Evolent guideline template<br>• This guideline replaces UM ONC_1475 Rezlidhia (olutasidenib) |
| February 2024 | • Updated NCH verbiage to Evolent<br>• Updated "continuation request" verbiage |

# LEGAL AND COMPLIANCE

## Guideline Approval

### *Committee*

**Reviewed / Approved by Evolent Specialty Services Clinical Guideline Review Committee**

## Disclaimer

*Evolent Clinical Guidelines do not constitute medical advice. Treating health care professionals are solely responsible for diagnosis, treatment, and medical advice. Evolent uses Clinical Guidelines in accordance with its contractual obligations to provide utilization management. Coverage for services varies for individual members according to the terms of their health care coverage or government program. Individual members' health care coverage may not utilize some Evolent Clinical Guidelines. Evolent clinical guidelines contain guidance that requires prior authorization and service limitations. A list of procedure codes, services or drugs may not be all inclusive and does not imply that a service or drug is a covered or non-covered service or drug. Evolent reserves the right to review and update*

*this Clinical Guideline in its sole discretion. Notice of any changes shall be provided as required by applicable provider agreements and laws or regulations. Members should contact their Plan customer service representative for specific coverage information.*

# REFERENCES


1. de Botton S, et al. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. *Blood Adv*. 2023 Jul 11;7(13):3117-3127. doi: 10.1182/bloodadvances.2022009411.
2. Watts JM, et al. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. *Lancet Haematol*. 2023 Jan;10(1):e46-e58. doi: 10.1016/S2352-3026(22)00292-7.
3. Rezlidhia prescribing information. Rigel Pharmaceuticals, Inc. South San Francisco, CA 2024.
4. Clinical Pharmacology Elsevier Gold Standard 2026.
5. Micromedex® Healthcare Series: Micromedex Drugdex Ann Arbor, Michigan 2026.
6. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium 2026.
7. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs. Bethesda, MD 2026.
8. Ellis LM, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. *J Clin Oncol*. 2014 Apr 20;32(12):1277-80.
9. Medicare Benefit Policy Manual Chapter 15 Covered Medical and Other Health Services: https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf.
10. Current and Resolved Drug Shortages and Discontinuations Reported to the FDA: http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm.